(6-methoxy-[1,1′-biphenyl]-3-yl)boronic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (6-methoxy-[1,1′-biphenyl]-3-yl)boronic acid
• 英文别名: (6-methoxy-[1,1'-biphenyl]-3-yl)boronic acid；3-phenyl-4-methoxyphenyl boronic acid；(4-methoxy-3-phenylphenyl)boronic acid
• 化学式: C₁₃H₁₃BO₃
• 分子量: 228.055
• InChiKey: OODAYTYTMKXJFO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.04
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  49.7
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (6-methoxy-[1,1′-biphenyl]-3-yl)boronic acid 在 四(三苯基膦)钯 、 吡啶盐酸盐 、 sodium carbonate 作用下， 以 乙醇 、 水 、 甲苯 为溶剂， 反应 21.0h， 生成 5-(2-pyridyl)-[1,1'-biphenyl]-2-ol
  参考文献：
  名称：

  METAL COMPLEXES FOR USE AS EMITTERS IN ORGANIC ELECTROLUMINESCENCE DEVICES

  摘要：

  本发明涉及金属配合物和电子设备，特别是含有所述金属配合物的有机电致发光器件。

  公开号：

  US20190161510A1
• 作为产物：
  描述：

  5-bromo-2-methoxy-1,1'-biphenyl 在 正丁基锂 、 硼酸三乙酯 、 盐酸 作用下， 以 四氢呋喃 、 正己烷 、 水 为溶剂， 生成 (6-methoxy-[1,1′-biphenyl]-3-yl)boronic acid
  参考文献：
  名称：

  New Insights into the SAR and Binding Modes of Bis(hydroxyphenyl)thiophenes and -benzenes: Influence of Additional Substituents on 17β-Hydroxysteroid Dehydrogenase Type 1 (17β-HSD1) Inhibitory Activity and Selectivity

  摘要：

  17 beta-Hydroxystcroid dehydrogenase type 1 (17 beta-HSD1) is responsible for the catalytic reduction of weakly active E1 to highly potent E2. E2 stimulates the proliferation of hormone-dependent diseases via activation of the estrogen receptor alpha (ER alpha). Because of the overexpression of 17 beta-HSD1 in mammary tumors, this enzyme should be an attractive target for the treatment of estrogen-dependent pathologies. Recently, we have reported on a series of potent 17 beta-HSD1 inhibitors: bis(hydroxyphenyl) azoles, thiophenes, and benzenes. In this paper, different substituents are introduced into the core structure and the biological properties of the corresponding inhibitors are evaluated. Computational methods and analysis of different X-rays of 17 beta-HSD1 lead to identification of two different binding modes for these inhibitors. The fluorine compound 23 exhibits an IC50 of 8 nM and is the most potent nonsteroidal inhibitor described so far. It also shows a high selectivity (17 beta-HSD2, ER alpha) and excellent pharmacokinetic properties after peroral application to rats.

  DOI：

  10.1021/jm901195w

文献信息

• Heterocyclic derivatives for the treatment of cancer and other proliferative diseases
  申请人：——

  公开号：US20020143182A1

  公开（公告）日：2002-10-03

  The invention relates to certain heterocyclic compounds useful for the treatment of cancer and other diseases, having the Formula (I): 1 wherein: (a) m is an integer 0 or 1; (b) R 12 is an alkyl, a substituted alkyl, a cycloalkyl, a substituted cycloalkyl, a heterocyclic, a substituted heterocyclic, a heteroaryl, a substituted heteroaryl, an aryl or a substituted aryl residue; (c) Ar 3 is an aryl, a substituted aryl, a heteroaryl or a substituted heteroaryl residue; (d) Ar 4 is an aryl, a substituted aryl, a heteroaryl or a substituted heteroaryl residue; (e) R 5 is hydrogen, hydroxy, alkyl or substituted alkyl; (f) - - - - - represents a bond present or absent; and (g) W, X, Y and Z are independently or together C(O)—, C(S), S, O, or NH; or a pharmaceutically acceptable salt thereof.

  该发明涉及某些对治疗癌症和其他疾病有用的杂环化合物，其具有以下式（I）： 1 其中： (a) m是整数0或1； (b) R12是烷基，取代烷基，环烷基，取代环烷基，杂环基，取代杂环基，杂芳基，取代杂芳基，芳基或取代芳基残基； (c) Ar3是芳基，取代芳基，杂芳基或取代杂芳基残基； (d) Ar4是芳基，取代芳基，杂芳基或取代杂芳基残基； (e) R5是氢，羟基，烷基或取代烷基； (f) - - - - - 代表存在或不存在的键；以及 (g) W、X、Y和Z独立或一起是C(O)、C(S)、S、O或NH；或其药学上可接受的盐。
• METAL COMPLEXES
  申请人：MERCK PATENT GMBH

  公开号：US20190315787A1

  公开（公告）日：2019-10-17

  The present invention relates to metal complexes and to electronic devices, in particular organic electroluminescent devices, containing these metal complexes.

  本发明涉及金属配合物和电子器件，特别是包含这些金属配合物的有机电致发光器件。
• New Insights into the SAR and Binding Modes of Bis(hydroxyphenyl)thiophenes and -benzenes: Influence of Additional Substituents on 17β-Hydroxysteroid Dehydrogenase Type 1 (17β-HSD1) Inhibitory Activity and Selectivity
  作者：Emmanuel Bey、Sandrine Marchais-Oberwinkler、Matthias Negri、Patricia Kruchten、Alexander Oster、Tobias Klein、Alessandro Spadaro、Ruth Werth、Martin Frotscher、Barbara Birk、Rolf W. Hartmann

  DOI：10.1021/jm901195w

  日期：2009.11.12

  17 beta-Hydroxystcroid dehydrogenase type 1 (17 beta-HSD1) is responsible for the catalytic reduction of weakly active E1 to highly potent E2. E2 stimulates the proliferation of hormone-dependent diseases via activation of the estrogen receptor alpha (ER alpha). Because of the overexpression of 17 beta-HSD1 in mammary tumors, this enzyme should be an attractive target for the treatment of estrogen-dependent pathologies. Recently, we have reported on a series of potent 17 beta-HSD1 inhibitors: bis(hydroxyphenyl) azoles, thiophenes, and benzenes. In this paper, different substituents are introduced into the core structure and the biological properties of the corresponding inhibitors are evaluated. Computational methods and analysis of different X-rays of 17 beta-HSD1 lead to identification of two different binding modes for these inhibitors. The fluorine compound 23 exhibits an IC50 of 8 nM and is the most potent nonsteroidal inhibitor described so far. It also shows a high selectivity (17 beta-HSD2, ER alpha) and excellent pharmacokinetic properties after peroral application to rats.
• METAL COMPLEXES FOR USE AS EMITTERS IN ORGANIC ELECTROLUMINESCENCE DEVICES
  申请人：Merck Patent GmbH

  公开号：US20190161510A1

  公开（公告）日：2019-05-30

  The present invention relates to metal complexes and electronic devices, in particular organic electroluminescent devices containing said metal complexes.

  本发明涉及金属配合物和电子设备，特别是含有所述金属配合物的有机电致发光器件。